A- A A+

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

Degenhardt, Louisa et al.

The Lancet Psychiatry, Volume 0, Issue 0 

Abstract

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00095-0/fulltext

'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue. 

Clay S, Treloar C, Degenhardt L, Grebely J, Christmass M, Gough C, Hayllar J, McDonough M, Henderson C, Crawford S, Farrell M, Marshall A. 

Int J Drug Policy. 2023 May;115:104002. doi: 10.1016/j.drugpo.2023.104002. Epub 2023 Mar 30. PMID: 37003194.

https://www.sciencedirect.com/science/article/pii/S0955395923000518

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series. 

Ochalek TA, Ringwood KJ, Davis TT, Gal TS, Wills BK, Sabo RT, Keyser-Marcus L, Martin CE, Polak K, Cumpston KL, Moeller FG. 

Drug Alcohol Depend Rep. 2023 Mar 16;7:100144. doi: 10.1016/j.dadr.2023.100144. PMID: 37033158; PMCID: PMC10073633.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073633/

Neu. Subutex Depot-Injektionslösungen

Ab 15. Mai wird die INDIVIOR Europe Ltd. folgendes Produkt im deutschen Markt anbieten:

Subutex 100 mg Depot-Injektionslösung in einer Fertigspritze / PZN 16512630

Subutex 300 mg Depot-Injektionslösung in einer Fertigspritze / PZN 16512647  

https://www.fachinfo.de/suche/fi/023932

A comparative study of sexual behavior, dysfunction, satisfaction, relationship, and sexual quality of life amongst treatment-naïve and abstinent men (buprenorphine-maintained) with Opioid (heroin) dependence syndrome. 

Sen MS, Chattopadhyay A, Chawla N, Ganesh R, Verma S, Sarkar S, Ambekar A. 

Indian J Psychiatry. 2023 Jan;65(1):75-82. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_395_22. Epub 2023 Jan 13. PMID: 36874522; PMCID: PMC9983461.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983461/

High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids. 

Snyder H, Chau B, Kalmin MM, Speener M, Campbell A, Moulin A, Herring AA. 

JAMA Netw Open. 2023 Mar 1;6(3):e231572. doi: 10.1001/jamanetworkopen.2023.1572. PMID: 36867410; PMCID: PMC9984967.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984967/

A Case Series of Spouses Undergoing Rapid Micro-Induction Technique of Buprenorphine Initiation from Methadone. 

Rampetsreiter KR, Salapenka I, Konakanchi JS, Anders J, Sethi R.

Kans J Med. 2023 Mar 15;16:74-78. doi: 10.17161/kjm.vol16.18433. PMID: 36970038; PMCID: PMC10035645.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035645/

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. 

D’Onofrio G, Hawk KF, Perrone J, et al. 

JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802898

Spülen nicht Putzen: Sublinguales Buprenorphin schlägt auf die Zähne

Bereits 2022 hatte die FDA auf Grundlage von Fallmeldungen Alarm geschlagen, nun hat eine kanadisch/US-amerikanische Studie die Vermutungen bestätigt: Sublinguales Buprenorphin kann die Zähne schädigen. Welche Empfehlungen können Anwender:innen mitgegeben werden? (DAZ – Deutsche Apothekerzeitung, 07.03.2023)

https://www.deutsche-apotheker-zeitung.de/news/artikel/2023/03/07/sublinguales-buprenorphin-schlaegt-auf-die-zaehne

FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 

Benefits for use outweigh these risks and oral care can help. (FDA – Food and Drugs Administration, USA, 21.01.2023)

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder

Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease. 

Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. 

JAMA. 2022;328(22):2269–2271. doi:10.1001/jama.2022.17485

Abstract

https://jamanetwork.com/journals/jama/article-abstract/2799415

Buprenorphine Maintenance in the Fentanyl Era: Challenges and Opportunities. 

Modesto-Lowe V, Jain L. 

Prim Care Companion CNS Disord. 2023 Feb 14;25(1):22l03336. doi: 10.4088/PCC.22l03336. PMID: 36821774.

https://www.psychiatrist.com/pcc/addiction/buprenorphine-maintenance-fentanyl-era-challenges-opportunities/

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021. 

Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, Ray B. 

Drug Alcohol Depend Rep. 2023 Mar;6:100131. doi: 10.1016/j.dadr.2023.100131. Epub 2023 Jan 4. PMID: 36777895; PMCID: PMC9910498.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910498/

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature. 

Ordean A, Tubman-Broeren M. 

Pathophysiology. 2023 Feb 11;30(1):27-36. doi: 10.3390/pathophysiology30010004. PMID: 36810423; PMCID: PMC9944489.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944489/

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. 

Gu M, Li A, Mak W, Dong F, Xu N, Zhang J, Shi Y, Zheng N, Tang Z, He Q, Ruan C, Guo W, Xiang X, Wang C, Han B, Zhu X. 

Front Pharmacol. 2023 Jan 19;14:1089862. doi: 10.3389/fphar.2023.1089862. PMID: 36744255; PMCID: PMC9893638.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893638/

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. 

Sun T, Katenka N, Kogut S, Bratberg J, Rich J, Buchanan A. 

Pharmacoepidemiology. 2022 Dec;1(3):101-112. doi: 10.3390/pharma1030010. Epub 2022 Nov 24. PMID: 36743423; PMCID: PMC9896393.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896393/

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder. 

Ito M, Walzer M, Beth Blauwet M, Spence A, Heo N, Kelsh D, Blahunka P, Erdman J, Nour Alsharif M, Marek GJ. 

J Psychopharmacol. 2023 Feb;37(2):144-154. doi: 10.1177/02698811221149657. Epub 2023 Feb 3. PMID: 36738100.

Abstract

https://journals.sagepub.com/doi/10.1177/02698811221149657

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study. 

Karavolis ZA, Roy PJ. 

Drug Alcohol Depend Rep. 2022 Oct 7;5:100104. doi: 10.1016/j.dadr.2022.100104. PMID: 36844162; PMCID: PMC9948859.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948859/

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. 

Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, Tsui JI, Levander XA, Korthuis PT. 

Addict Sci Clin Pract. 2023 Feb 14;18(1):11. doi: 10.1186/s13722-023-00364-3. PMID: 36788634; PMCID: PMC9930351.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930351/

HOW DO PATIENTS FEEL DURING THE FIRST 72 HOURS AFTER INITIATING LONG-ACTING INJECTABLE BUPRENORPHINE? AN EMBODIED QUALITATIVE ANALYSIS. 

Neale, J, Parkin, S, Strang, J. 

Addiction. 2023; 000– 0., doi.org/10.1111/add.16171

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.16171

Extended-release monthly buprenorphine injection. 

Cuperfain AB, Costa T, Chopra N. 

CMAJ. 2023 Jan 9;195(1):E14. doi: 10.1503/cmaj.220730. PMID: 36623857; PMCID: PMC9829071.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829071/

Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.

Seval, Nikhil MD; Nunez, Johnathan MD; Roth, Prerana MD; Schade, Meredith MD; Strong, Michelle MSN, FNP-BC; Frank, Cynthia A. PhD; Litwin, Alain H. MD, MPH, MS; Levin, Frances R. MD; Brady, Kathleen T. MD, PhD; Nunes, Edward V. MD; Springer, Sandra A. MD. 

Journal of Addiction Medicine ():10.1097/ADM.0000000000001136, January 26, 2023. | DOI: 10.1097/ADM.0000000000001136 

Abstract

https://journals.lww.com/journaladdictionmedicine/Abstract/9900/Inpatient_Low_dose_Transitions_From_Full_Agonist.145.aspx

A Novel Inpatient Buprenorphine Induction Program for Adolescents With Opioid Use Disorder. 

Trope LA, Stemmle M, Chang A, Bashiri N, Bazazi AR, Lightfoot M, Congdon JL. 

Hosp Pediatr. 2023 Feb 1;13(2):e23-e28. doi: 10.1542/hpeds.2022-006864. PMID: 36683456.

https://publications.aap.org/hospitalpediatrics/article/13/2/e23/190497/A-Novel-Inpatient-Buprenorphine-Induction-Program

Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: A case series. 

Spadaro A, Faude S, Perrone J, Thakrar AP, Lowenstein M, Delgado MK, Kilaru AS. 

J Am Coll Emerg Physicians Open. 2023 Jan 23;4(1):e12880. doi: 10.1002/emp2.12880. PMID: 36704210; PMCID: PMC9871399.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871399/

The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment. 

McGee M, Chiu K, Moineddin R, Sud A. 

Appl Health Econ Health Policy. 2023 Jan 18. doi: 10.1007/s40258-022-00787-0. Epub ahead of print. PMID: 36652186.

https://link.springer.com/article/10.1007/s40258-022-00787-0

Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder. 

Salapenka I, Konakanchi JS, Sethi R. 

Prim Care Companion CNS Disord. 2022 Dec 27;24(6):21cr03150. doi: 10.4088/PCC.21cr03150. PMID: 36584361.

https://www.psychiatrist.com/pcc/addiction/outpatient-rapid-microinduction-of-sublingual-buprenorphine-in-3-days-from-methadone-for-opioid-use-disorder/

Buprenorphine Microdosing Cross Tapers: A Time for Change. 

Raheemullah A, Benhamou OM, Kuo J, Lembke A. 

Int J Environ Res Public Health. 2022 Dec 8;19(24):16436. doi: 10.3390/ijerph192416436. PMID: 36554317; PMCID: PMC9778657.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778657/

Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. 

Baxley C, Borsari B, Reavis JV, Manuel JK, Herbst E, Becker W, Pennington D, Batki SL, Seal K. 

Addict Behav. 2022 Dec 17;139:107589. doi: 10.1016/j.addbeh.2022.107589. Epub ahead of print. PMID: 36565531.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36565531/

Transferring patients from high-dose methadone to buprenorphine: A retrospective case series. 

Foran A, Tremonti C, Balgobind V, Sakr H, Murnion B. 

J Opioid Manag. 2022 Nov-Dec;18(6):557-566. doi: 10.5055/jom.2022.0752. PMID: 36523207.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36523207/

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. 

Laffont CM, Ngaimisi E, Gopalakrishnan M, Ivaturi V, Young M, Greenwald MK, Heidbreder C. 

Front Pharmacol. 2022 Nov 18;13:1052113. doi: 10.3389/fphar.2022.1052113. PMID: 36467036; PMCID: PMC9715596.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715596/

  1. Suboxone: History, controversy, and open questions. 
  2. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation. 
  3. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review. 
  4. Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis. 
  5. How do I interpret and use quantitative buprenorphine and norbuprenorphine urine levels?